Meet Our Board of Directors

Our board of directors brings extensive expertise in pharmaceutical development, oncology, and healthcare operations to Panavance.  

Greg Bosch

Chairman & CEO

LinkedIn

Greg Bosch brings over 30 years in healthcare to Panavance with leadership of commercial, operations, and R&D teams in the US and Europe. His general management experience in the life science industry spans the pharmaceutical, biologics and medical device segments including building a biosurgery business to $220M in 5 years, acquiring public and private companies, and taking public a company.  Prior to joining Panavance Greg was Chief Executive Officer of Geistlich Pharma North America where he led a cross functional team to achieve the market leadership position in regenerative medicine in the US dental field. While at Geistlich, he also led the company’s global oncology program and was responsible for the team developing Panavance’s proprietary small molecule drug compound GP-2250 from early R&D through to the clinical studies. Earlier in his career he was the President and Chief Executive Officer of PuriCore PLC where he led a successful IPO on the London Stock Exchange. Prior to his experience with PuriCore he held roles of increasing responsibility at Baxter International including General Manager of the BioSurgery Business, Vice President of Strategic Planning and Assistant to the President. Greg currently serves on the Board of Kibow Biotech, Inc. Greg earned his B.A. in Public Policy from Duke University and MBA from DePaul University.

Greg Bosch Headshot

Greg Bosch

Chairman & CEO

 

James Brady

Chair, Audit Committee

LinkedIn

James Brady is an experienced international business executive who served in multiple leadership roles of increasing responsibility for AstraZeneca prior to his retirement. His more than thirty years of progressive experience at AstraZeneca included successful national, regional and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery & development. James most recently served as Chief Financial Officer of MedImmune, the biologics division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market. Throughout his career at AstraZeneca, James had P&L and management responsibilities for significant operating units and finance functions including MedImmune, the Asia Pacific Region, US Government, Policy and Managed Markets, and Global Marketing. James also served as the Chief Audit Executive for AstraZeneca. His experience spans the full product development cycle from early research and clinical development to sales and product contracting. James currently serves as a Non-Executive Director on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA). He previously served on the Board of Directors, the Executive Committee and as Chair of the Audit & Finance Committee of the Montgomery County, Maryland Economic Development Corporation. James is a CPA and worked at Arthur Andersen & Company. He holds a B.S in Accounting from Saint Joseph University and an MBA from Drexel University.

James Brady Headshot

James Brady

Chair, Audit Committee

 

Cindy Collins

Lead Director & Chair, Compensation Committee

LinkedIn

Cynthia (Cindy) Collins, is a recognized leader in cell and gene therapy, genomic medicine, molecular diagnostics, life sciences, and therapeutics. Prior to her most recent position as CEO of Editas Medicine (Nasdaq:EDIT), she served as CEO of Human Longevity Inc, a genomics-based company.  Prior to Human Longevity Cindy served as CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics. Before GE, Cindy served as President and CEO of GenVec (Nasdaq:GNVC) and Group Vice President, Cellular Analysis Business of Beckman Coulter. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals. Earlier, Cindy served as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President & General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent 6 years in various operating roles.  Cindy received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business. Cindy is a member of the board of directors of DermTech (Nasdaq:DMTK), Certara (Nasdaq:CERT), and Poseida Therapeutics (Nasdaq:PSTX).

Cindy Collins

Cindy Collins

Lead Director & Chair, Compensation Committee

 

Marla Persky

Chair, Nomination & Governance Committee

LinkedIn

Marla Persky is CEO and President of WOMN LLC, a company dedicated to helping women succeed in the business of law by increasing their knowledge of and acuity with financial drivers, client development, and leadership. Marla retired in 2013 as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim Inc., where she oversaw a department of over 70 individuals. She was a member of Boehringer’s executive management team and a director of the company and several of its subsidiaries. Prior to joining Boehringer Ingelheim, Marla spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. Marla currently serves on the Audit and Chairs the Governance Committees of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a specialty pharmaceutical company that leverages proprietary non-aqueous formulation technology platforms. Additionally, she is on the Board of Directors of REVOLO Biotherapeutics which develops therapies to reset the immune system to achieve long-term remission for patients with autoimmune and allergic diseases. Ms. Persky also serves on the Audit and Strategic Planning Committees of the Board of Directors of YGEIA, a medical informatics technology company. Previously, she served on the Board of Directors of Cytyc Corporation (NASDAQ: CYTYC) a device and diagnostics company. In addition to her corporate activities, Ms. Persky is on the Board of several not-for-profit organizations such as the Leukemia & Lymphoma Society, Primary Stages (Off-Broadway Theater Company) and World Neighbors Inc.

Marla Persky Headshot

Marla Persky

Chair, Nomination & Governance Committee

 

Erich Platzer

Board Member

LinkedIn

Dr. Erich Platzer brings expertise in financing startup companies focused on life sciences to Panavance. He is currently the chairman of Alzheimer company Vivoryon Therapeutics NV (Euronext, Amsterdam) and board member of oncology focused Aptose Biosciences Inc (NASDAQ, TSE). He serves as Chairman or board member of Swiss private companies AOT, LMD, and Peripal. He is a Board member and HealthcarePartner of Swiss VC firm MTIP which is focused on digital health. Dr. Platzer has been a Business Angel since 2010; and President of StartAngelsNetwork, Switzerland. From 2001 to 2015 he was co-founder and investment advisor of HBM BioVentures (now HBM Healthcare Invest­ments). He has had multiple roles as chairman or board member of various biotech companies, public or private. Dr. Platzer spent 10 years at Roche (development and business) with his last position as therapeutic area head business oncology. Prior to his roles in industry he spent 12 years in academic medicine and research and was the co-lead team that purified human G-CSF at MSKCC, licensed to Amgen (Neupogen®). Dr Platzer is board certified for Internal Medicine, Hematology and Medical Oncology.  He is a medical faculty member at University of Erlangen, Germany since 1989: Dr. med. habil (~M.D.Ph.D.).

Erich Platzer

Erich Platzer

Board Member